A “significant further decline” of glyphosate sales could push Bayer towards a breakup of its agriculture business.
Glyphosate was listed as a probable human carcinogen by the World Health Organization’s International Agency for Research on Cancer in 2015.
Bayer said it plans to replace glyphosate-based weed-killing ingredients in products for non-professionals in the U.S. with alternative active ingredients in order to “manage litigation risk in the U.S.,” but not due to concerns about safety.
Monsanto owner, Bayer AG, is contemplating pulling the popular herbicide from the residential market as it struggles to cement a strategy to limit ongoing litigation.
“Removing glyphosate from residential use would be a step in the right direction.”
“It’s a slam dunk for plaintiffs. This proves these claims are viable in the tort system.”
“Will they continue the pattern of doing the bidding of global biotech/seed firms like Monsanto? Or, will the USTR respect other countries’ rights to protect the environment and indigenous crops?”
The court said that Monsanto’s argument that scientific findings about glyphosate’s links to cancer constituted a “minority view” was not supported.
Bayer will have to pay between "$8.8 billion to $9.6 billion to resolve current Roundup lawsuits."